We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Proteinuria Contributes to Greater CKD Progression Risk in Men

By LabMedica International staff writers
Posted on 29 Aug 2019
Print article
Image: A photomicrograph showing numerous completely sclerotic glomeruli and severe chronic tubulointerstitial nephritis from a patient with end-stage kidney disease (Photo courtesy of Dr. Jian-Hua Qiao, MD, FCAP).
Image: A photomicrograph showing numerous completely sclerotic glomeruli and severe chronic tubulointerstitial nephritis from a patient with end-stage kidney disease (Photo courtesy of Dr. Jian-Hua Qiao, MD, FCAP).
Older men with chronic kidney disease had a 50% increased risk for progression to end-stage kidney disease (ESKD) compared with women and this may be the result of higher levels of proteinuria.

End stage kidney disease is the last stage (stage five) of chronic kidney disease (CKD). This means kidneys are only functioning at 10% to 15% of their normal capacity. When kidney function is this low, they cannot effectively remove waste or excess fluid from the blood.

A team of scientists working with the University of Campania (Naples, Italy) evaluated the impact of gender on CKD progression, and conducted a pooled analysis of four observational cohort studies, which included a total of 2,335 men and women with an eGFR of less than 45 mL/min/1.73m2 (mean age, 67.1 years; mean eGFR, 26.9 mL/min/1.73m2). While age, systolic blood pressure and use of renin-angiotensin system inhibitors were similar between men and women, women had a lower median proteinuria (protein excretion, 0.45 g/d) compared with men (0.69 g/d).

The team reported that during a median follow-up of 4.2 years, 757 developed ESKD (59.4% men) and 471 died (58.4% men). The adjusted risks for ESKD and mortality were higher in men (Hazard Ratios (HRs) of 1.50 and 1.30 respectively). This finding was consistent across CKD stages. They observed a significant interaction between gender and proteinuria, with the risk for ESKD in men being significantly greater than for women at a level of proteinuria of ∼0.5 g/d or greater. When examining eGFR, they concluded that the slope of decline in eGFR was steeper in men than in women and that the difference in slopes between men and women was progressively larger with proteinuria less than 0.50 g/d.

The team concluded that data obtained from patients with clinical features consistent with the epidemiologic pattern of the present CKD population worldwide, namely advanced age and high prevalence of diabetes and cardiovascular disease. Still, although their study had some limitations, the results derive from a population of referred white patients with CKD and therefore findings may not hold true for other ethnic groups. Despite this limitation, proteinuria levels may modify the association between sex and renal risk.

Roberto Minutolo, MD, PhD, a Professor of Nephrology, and lead author of the study said, “The importance of sexual dimorphisms has been observed for hypertension and cardiovascular complications with regard to disease presentation, likelihood of progression to advanced phases and response to treatment. To date, the impact of sex on CKD remains poorly defined. In this setting, the mechanisms underlying the observed sex disparity in the epidemiology of kidney diseases have not been fully elucidated.” The study was published on August 10, 2019, in the American Journal of Kidney Diseases.

Related Links:
University of Campania

Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Silver Member
ACTH Assay
ACTH ELISA
New
Community-Acquired Pneumonia Test
RIDA UNITY CAP Bac

Print article

Channels

Molecular Diagnostics

view channel
Image: The Mirvie RNA platform predicts pregnancy complications months before they occur using a simple blood test (Photo courtesy of Mirvie)

RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms

Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Deliver Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.